Deeper patient insights for stronger patient outcomes
pharmafile | October 28, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | eyeforpharma, pharma
Patient insights are crucial. As you already know, they are the key to the creation of successful, targeted programmes and even brand-new product offerings. They dictate the delivery of successful outcomes.
But if we are to gain deeper, richer insights, we must construct frameworks that help more patients articulate their value-drivers and hit on critical touchpoints.
That’s why at eyeforpharma we’ve put together a webinar (2pm GMT/9am EST, 6 November), with an expert panel, to provide pragmatic tools on how to build smarter frameworks for new understanding that leads to targeted, personalised services, and ultimately, greater outcomes.
The panel includes: Daniel De Schryver (Patient Engagement and Advocacy Lead, EMEA, Janssen); Clare Moloney (Programme Insights & Design Lead, IQVIA); Desiree Priestley (Director, Patient Support Strategy & Insights, Otsuka); Oliver Gassner (Head, Digital Health Intelligence, EMEA, Bayer); and Teresa Ferreiro (Patient Advocate & eyeforpharma Award Winner)
By joining, you’ll learn:
- Why designing frameworks with the patient in mind is insufficient: Work with patients from the beginning to ensure you collect comprehensive and pertinent insights
- How to build your business case: Use insights to outline the commercial imperative of new services
- It’s not just patients: When and how to engage HCPs and carers to gather a holistic view on how programmes can best operate
We look forward to a webinar that promises practical advice on how to vastly improve the likelihood of success when building new programmes that deliver maximum patient value.
Registrations are now open here: http://bit.ly/2BEBq13
*All signups receive the recording – so if you can’t make it on the day, sign up anyway and you’ll get the on-demand version
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
